REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries
REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries.
RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morbidity and mortality. Despite the use of prophylactic immunosuppressive therapy, clinically significant aGvHD develops in 20%-40% of HLA-matched related and unrelated allogeneic HSCT and severe cases contribute to non-relapse mortality.
Under the terms of agreement, REGiMMUNE and SFB will collaborate closely to accelerate the development of RGI-2001 in major Asian countries and will conduct clinical trials to study the efficacy of the drug in aGvHD. Together, both parties intend to submit an Investigational New Drug Application to the Taiwan Food and Drug Administration to initiate clinical trials in Taiwan for the prophylaxis of aGvHD before the end of 2023. SFB will pay to REGiMMUNE development milestones and royalties on net profit upon successful commercialization of RGI-2001. SFB also retains the first rights of negotiation to develop and commercialize RGI-2001 for new indications in the authorized territories.
RGI-2001 of REGiMMUNE, awarded Orphan Drug Designation by the US FDA in GvHD in 2012, has completed the phase II clinical trial targeting at the prophylaxis of aGvHD in the US. The efficacy and safety results were positive. Furthermore, RGI-2001 was selected for oral presentation at the American Society of Hematology (ASH) annual meeting in December 2022 and planned to submit phase III IND to US FDA in Q4 of 2023.
Kenzo Kosuda, Chief Executive Officer and President, REGiMMUNE Limited, said: “This agreement underscores our focus and commitment to improve the incumbent therapies of aGvHD prevention and treatment. The fast-growing patients with GvHD in Asia create a high unmet need for more effective treatments. ”
“We are pleased to collaborate with SFB and San Fu Chemical Group which has a long history in Taiwan. The Group’s abundant biomedical resources, expertise and innovative strategy make San Fu a strong commercial partner for REGiMMUNE in Asia. Together, we look forward to expediting the development of RGI-2001 in this important market.”
Simon H.H. Wu, SFB & San Fu Chemical Group Chairman, emphasized: “We are excited to add RGI-2001 to our growing portfolio of innovative therapeutic agents. This enhances our autoimmune pipeline and aligns with our long-term research and development strategy. RGI-2001 has demonstrated promising results in phase II studies in the US and we look forward to working together with REGiMMUNE to deliver treatments that will benefit the lives of patients.”
About RGI-2001
RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT). Liposomal alpha-GalCer promotes tolerogenic immune cascades, resulting in the activation and expansion of regulatory T cells (Tregs).
RGI-2001 is REGiMMUNE’s lead drug candidate currently in Phase 3 planning for the prophylaxis of acute graft-versus-host disease (aGVHD).
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
About San Fu Biotech
San Fu Biotech, a wholly-owned subsidiary of San Fu Chemical, develops first-in-class new drugs to address unmet medical needs, such as cancer tumors, autoimmune disease and ophthalmology, for benefiting patients around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230401005026/en/
Contact information
Charlie Hsu
Chief Financial Officer
REGiMMUNE Ltd.
Tel: +886 2 2555 3377 #511
Email: charlieh@regimmune.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Expands AI-Enablement Capabilities with Addition of NextGen Invent30.7.2025 16:30:00 EEST | Press release
Andersen Consulting enters into a Collaboration Agreement with NextGen Invent, an AI enablement and technology services company focused on delivering innovative, data-centric solutions, strengthening the organization’s digital transformation platform by integrating advanced data science, AI, and intelligent automation capabilities. Headquartered in the U.S., NextGen Invent brings deep expertise in generative AI, machine learning, data strategy, advanced analytics, digital product development, IoT, and intelligent automation. Their solutions are behind some of the most recognizable brands in the healthcare, financial services, life sciences, and manufacturing industries. With a strong emphasis on innovation, NextGen Invent helps organizations across these industries to accelerate digital maturity, optimize operations, and uncover new opportunities for growth. The company is known for its technology thought leadership and ability to drive business outcomes through intelligent insights. “
Armis Honored with Inaugural Wiz Integrations (WIN) Partner Award30.7.2025 16:00:00 EEST | Press release
Armis, the cyber exposure management & security company, has been recognized by Wiz as a winner in the inaugural WIN awards, earning the WINspiration Award for its outstanding partnership. This recognition highlights Armis' track record of delivering real outcomes for joint customers through the WIN program. Armis, recognized for its commitment to customer success and innovation, brings the power of Armis Centrix™, the Armis Cyber Exposure Management Platform, to WIN, enabling customers to seamlessly integrate Wiz into their existing workflows. This partnership empowers Wiz and Armis to share prioritized security findings with context, including inventory, vulnerabilities, issues and configuration findings. Mutual customers can operationalize the remediation lifecycle by: Gaining deep situational awareness of every asset and its details across the digital landscape Consolidating, contextualizing and prioritizing Wiz findings in Armis based on asset profile and business risk weighting A
Telness Tech Appoints Octopus Group Chairman John Browett to Board of Directors30.7.2025 15:30:00 EEST | Press release
Telness Tech, the rapidly growing tech company reinventing telecom for modern mobile operators, today announced the appointment of John Browett to its Board of Directors. Browett brings decades of leadership and governance experience from some of the world’s most prominent companies, including Octopus Group, Apple, and Tesco. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730862294/en/ John Browett to join Telness Tech Board of Directors Browett currently serves as Chairman of Octopus Group, the company who founded Octopus Energy, whose Kraken Technologies platform has redefined how technology can transform traditional industries. He has also held executive leadership roles at Apple and Tesco, helping scale globally recognized businesses and pioneer large-scale e-commerce in one of Europe’s most competitive retail environments. “Telness Tech is doing to telecom what Kraken has done to the energy sector — rewriting the rul
Regula and Indicio Partner to Transform Identity Verification With Verifiable Credentials30.7.2025 15:30:00 EEST | Press release
Regula, a global developer of identity verification (IDV) solutions and forensic devices, enters a strategic technology partnership with Indicio, a market leader in Verifiable Credential technology and decentralized identity solutions. Together, the two companies will deliver a breakthrough in portable digital trust by issuing document and biometric identity verification solutions as tamper-proof Verifiable Credentials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730663365/en/ Regula x Indicio: Bridging the gap between physical IDs and tamper-proof digital credentials This collaboration between Regula and Indicio delivers a holistic infrastructure for creating, storing, and verifying digital identities, underpinned by the most robust verification technologies available today. After decades of forensic expertise and innovation in document and biometric verification technology, Regula has the most complete set of ID auth
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+30.7.2025 15:09:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield™ blood test. Approved by the U.S. Food and Drug Administration (FDA) last year, Shield offers a convenient and more pleasant new option for CRC screening for eligible individuals 45+. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250728751799/en/ Known for iconic roles in Varsity Blues, Rules of Attraction and Don’t Trust the B in Apartment 23, Van Der Beek has created many memorable characters in his 20+-year TV and film career, both on screen and as a producer, director and writer. Van Der Beek went public with his CRC diagnosis in November 2024 to encourage others to take control of their health. Today marks the first time he is speaking out about the critical importance of staying up to date
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom